This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

BeOne Medicines Ltd.
11/5/2026
Good day everyone. Welcome to B1 Medicine's Q3 2026 earnings call webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. At this time, I would like to turn the call over to the company.
Hello and welcome. Thanks for joining us today. I'm Dan Maller, Head of Investor Relations at V1 Medicines. Before we begin, please note that you can find additional materials, including a replay of today's webcast and presentation, on the Investor Relations section of our website, ir.v1medicines.com. I would like to remind all participants that during this call, we may make forward-looking statements regarding, among other things, the company's future prospects and business strategy. Actual results may differ materially from those indicated in Thank you for joining us. Now turning to today's call as outlined on slide three. John Oyler, our co-founder, chairman, and CEO, will provide a business update. Aaron Rosenberg, our CFO, will provide an update on our third quarter financial results and 2026 financial guidance. And Lai Wang, president and global head of R&D, will discuss our R&D and pipeline progress. We will then open the call for questions. Joining the team for the Q&A portion of the call will be Xiaobin Wu, president and chief operating officer, Matt Chalas, our General Manager of North America, Mark Lanasa, Chief Medical Officer for Solid Tumors, and Ahmed Agarwal, Chief Medical Officer for Hematology. I'll now pass the call over to John. John?
Thank you, Dan, and welcome. I'm pleased to present our Q3 results today across every dimension of the business. V1 is executing at the very highest level in our history. The results speak for themselves. Financially, we continue to deliver rapid growth and strong earnings. Aaron will take you through that shortly. In hematology, Brukinza's powerful and sustained BTK inhibition continues to translate into clinical and real-world differentiation. Building on Brukinza, Bacalzi and Tachybrutidae are expanding our leadership and extending it well into the future. In solid tumors, We're living up to our promise that 2026 would be an inflection year. Last week, we shared data for three of our most promising programs at ESMO. We have now shared differentiated data for five pivotal late-stage solid tumor programs. We've reached a level of productivity that I think is very rare in our industry. And the model we have worked so hard to build is already delivering very tangible results and we've only just begun to scratch the surface of what's possible. Here we see Rukinza's performance for the quarter. Sales totaled $1.4 billion, growing 34% year over year, with U.S. sales exceeding $1 billion for the quarter for the first time. The underlying fundamentals continue to be very strong. Rukinza's not just a leader in CLL. It's a powerful treatment option across four other B-cell malignancies. And we are far from done. Brekenza, both as a single agent and in combination, continues to generate the most Phase III data across the BTKI class. We often talk about Brekenza's clinical differentiation. It was designed for complete and sustained BTK inhibition, and it remains the only CLL therapy to show PFS superiority over a Grutinib in a head-to-head trial. The results we see in the clinical trial data for Grutinza are increasingly reinforced in the real world, and the picture is remarkably consistent. This slide brings together six independent datasets in CLL, representing tens of thousands of patients across three endpoints, overall survival, Time to discontinuation and time to next treatment. Across all of it, the answer is the same.
You're reading a preview of the ONC Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing